NCCN Guidelines for Patients® | Melanoma - page 105

105
NCCN Guidelines for Patients
®
: Melanoma
Version 1.2013
Index
Ablative therapy
34, 41, 59, 60, 64
Adjuvant treatment
38, 39, 54, 55, 59–61, 70, 74
Biopsy
18, 19, 21–23, 30, 35, 46, 47, 51–55, 58–60,
63–65, 68, 69
Cancer stage, staging
19, 26–33, 51, 52, 58, 59, 63, 64,
68, 69, 82, 83
Caregivers
75–78
Chemotherapy
36–38, 46, 60, 72, 73
Clinical stage
30–32, 51–55, 58–60, 63, 64, 68
Clinical trial
40, 42, 54, 55, 59, 60, 63–71
Complementary and alternative medicine (CAM)
41
Dermis
6, 8–11, 18, 19, 32, 53, 62
Epidermis
6, 8, 18, 19, 28, 29, 32, 53, 62
Follow-up test
56, 57, 61, 62, 71, 83
Immunotherapy
36, 38–40, 47, 48, 60, 72
In-transit
9, 29, 41, 58–60, 62–65, 74
Lymph node
8, 9, 17, 19, 21, 22, 27, 29, 32, 35–37, 53,
57–67, 71, 74
Melanin
6, 8, 13
Melanocyte
6, 8
Member Institutions
100, 103, 104
Metastases, metastatic
19, 29–32, 38–40, 60, 61, 68–74
National Comprehensive Cancer Network (NCCN)
2, 100
Palliative
59, 60, 64, 74
Panel members
101, 102
Pathologic stage
30–32, 55, 58–60
Pathology report
19–21, 51, 52
Primary treatment
35, 38, 54, 59–61
Radiation therapy
40, 48, 59, 60, 64, 66, 67, 69, 70, 74
Recurrence
55–57, 61–68, 71, 74
Satellite
9, 29, 32, 41, 62–65, 74
Side effects
38, 39, 45–49, 72, 73, 82, 83
Supportive care
66, 67, 69–71
Surgery
19, 21, 22, 35–38, 46, 54, 55, 59–61, 65–67, 69,
70
Lymph node dissection
36, 46, 47, 59–61, 66, 67
Wide excision
35, 54, 59–61, 64, 65
Survivorship
83
Symptom
11, 17, 22, 48, 51
Systemic therapy
36–40, 59, 60, 64–67, 69–73
Targeted therapy
40, 47, 63, 68, 69, 72
Cancer tests
16–25
Blood tests
22, 53, 56, 62, 68, 71
Imaging tests
22, 29, 30, 53, 56–59, 61–6468–71
Tissue tests
18, 21
Treatment planning
16, 27
Vaccine therapy
40
1...,95,96,97,98,99,100,101,102,103,104 106,107,108
Powered by FlippingBook